1. Catalog
  2. OnDemand: Grand Rounds- May 2026: Artificial Intel ...
OnDemand: Grand Rounds- May 2026: Artificial Intelligence and the Changing Landscape of Obesity Medicine
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $50.00
Credit Offered
1 AMA PRA Category 1 Credit
This talk introduces artificial intelligence in the context of obesity medicine and reviews how AI is being applied to understand disease heterogeneity, predict treatment response, and support longitudinal care. The session also examines how digital technologies and AI are transforming obesity practice and influencing the broader evolution of clinical medicine
1. Describe key concepts of AI and its applications in obesity medicine, including disease phenotyping and prediction of treatment response.
2. Evaluate AI-enabled tools and digital health technologies for their clinical validity, utility, and limitations in obesity care.
3. Apply AI-driven insights and digital technologies in clinical practice to support personalized, longitudinal obesity management while considering ethical and equity implications.
Gitanjali Srivastava MD, MEng, FAAP, FACP, FTOS
Professor of Medicine, Pediatrics & Surgery & Chief of Obesity Medicine at Vanderbilt University
Gitanjali Srivastava, MD, MEng FAAP, FACP, FTOS is Professor of Medicine, Pediatrics & Surgery & Chief of Obesity Medicine at Vanderbilt University in Nashville, Tennessee.  Dr. Srivastava is a physician-scientist with >15 years senior leadership experience in clinical & translational research, medical education, innovation in AI/ML (including digital health), clinical care, and healthcare systems with breadth of experience bridging academia with biopharma partnerships and external KOL engagements. She was most recently honored by CIO Views Magazine on its cover page as the #1 Most Impact-Driven Women Business Leaders in the World Leading Change in 2026 for transforming obesity medicine through her visionary leadership and innovation.
The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Release: June 15, 2026
Date of Termination: December 31, 2028
No commercial support was received for this activity.
Gitanjali Srivastava, MD: Corporate Advisory Board relationship with Lilly, NovoNordisk (Pharmaceuticals) Speakers Bureau relationship with Rhythm (Pharmaceuticals) Advisor relationship with Boehringer Ingelheim, Madrigal (pharmaceuticals), Quest Diagnostics (Biomedical) Researcher relationship with Recordati, Eli Lilly (Pharmaceuticals)
Sriram Machenini, MD: Advisor relationship with Abbie Inc. (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and NeurogastriX (Pharmaceuticals) Consultant relationship with Rhythm (Pharmaceuticals)

Angela Golden, DNP: Advisor relationship with Acella (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Acella (Pharmaceuticals), Currax (Pharmaceuticals), Eli Lilly (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals)
No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.
1. Huang L, Huhulea EN, Abraham E, Bienenstock R, Aifuwa E, Hirani R, Schulhof A, Tiwari RK, Etienne M. The Role of Artificial Intelligence in Obesity Risk Prediction and Management: Approaches, Insights, and Recommendations. Medicina (Kaunas). 2025 Feb 19;61(2):358. doi: 10.3390/medicina61020358. PMID: 40005474; PMCID: PMC11857386.

2. Azmi S, Kunnathodi F, Alotaibi HF, Alhazzani W, Mustafa M, Ahmad I, Anvarbatcha R, Lytras MD, Arafat AA. Harnessing Artificial Intelligence in Obesity Research and Management: A Comprehensive Review. Diagnostics (Basel). 2025 Feb 6;15(3):396. doi: 10.3390/diagnostics15030396. PMID: 39941325; PMCID: PMC11816645.

3. Kim DW, Park CY, Shin JH, Lee HJ. The Role of Artificial Intelligence in Obesity Medicine. Endocrinol Metab Clin North Am. 2025 Mar;54(1):207-215. doi: 10.1016/j.ecl.2024.10.008. Epub 2024 Nov 12. PMID: 39919876.
Powered By